High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease

Chest

Volumn 134, Issue 2, 2008, Pages 358-367

  Goldin, Jonathan G ^a,e   Lynch, David A ^b   Strollo, Diane C ^c   Suh, Robert D ^a   Schraufnagel, Dean E ^d   Clements, Philip J ^a   Elashoff, Robert M ^a   Furst, Daniel E ^a   Vasunilashorn, Sarinnapha ^a   McNitt Gray, Michael F ^a   Brown, Mathew S ^a   Roth, Michael D ^a   Tashkin, Donald P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CT scan; Lung disease; Scleroderma

Indexed keywords

CYCLOPHOSPHAMIDE; PLACEBO;

ADULT; ARTICLE; BRONCHIECTASIS; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; EMPHYSEMA; FEMALE; FOLLOW UP; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA;

EID: 49449107888     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-2444     Document Type: Article

References (44)

1. Arroliga AC, Podell DN, Matthay RA. Pulmonary manifestations of scleroderma. J Thorac Imaging 1992; 7:30-45
2. Geppert T. Clinical features, pathogenic mechanisms, and new developments in the treatment of systemic sclerosis. Am J Med Sci 1990; 299:193-209
3. Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1990; 176:755-759
4. Geirsson AJ, Wollheim FA, Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis 2001; 60:1117-1122
5. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581-1586
6. Kim DS, Yoo B, Lee JS, et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:121-127
7. Minai OA, Dweik RA, Arroliga AC. Manifestations of scleroderma pulmonary disease. Clin Chest Med 1998; 19:713-731, viii-ix
8. Warrick JH, Bhalla M, Schabel SI, et al. High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991; 18:1520-1528
9. Seely JM, Jones LT, Wallace C, et al. Systemic sclerosis: using high-resolution CT to detect lung disease in children. AJR Am J Roentgenol 1998; 170:691-697
10. Remy-Jardin M, Remy J, Wallaert B, et al. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology 1993; 188:499-506
11. Fujita J, Yoshinouchi T, Ohtsuki Y, et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001; 60:281-283
12. Tashkin DP, Elashoff RM, Clements PJ, et al. The Scleroderma Lung Study: oral cyclophosphamide versus placebo for the treatment of scleroderma-related interstitial lung disease. N Engl J Med 2006; 354:2655-2666
13. American Rheumatism Association. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23:581-590
14. Clements PJ, Medsger TA. Cutaneous involvement. In: Clements PJ, Furst DE, eds. Systemic sclerosis. Philadelphia, PA: Lippincott Williams & Wilkins, 2004; 129-150
15. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169: 977-983
16. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152:1107-1136
17. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique; 1995 update. Am J Respir Crit Care Med 1995; 152:2185-2198
18. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132:947-954
19. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20:838-844
20. Behr J, Vogelmeier C, Beinert T, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996; 154:400-406
21. Ettensohn DB, Jankowski MJ, Duncan PG, et al. Bronchoalveolar lavage in the normal volunteer subject: I. Technical aspects and intersubject variability. Chest 1988; 94:275-280
22. Ettensohn DB, Jankowski MJ, Redondo AA, et al. Bronchoalveolar lavage in the normal volunteer subject: 2. Safety and results of repeated BAL, and use in the assessment of intrasubject variability. Chest 1988; 94:281-285
23. Altman DG. Practical statistics for medical research. London, UK: Chapman and Hall, 1991
24. Remy-Jardin M, Giraud F, Remy J, et al. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993; 189: 693-698
25. Pignone A, Matucci-Cerinic M, Lombardi A, et al. High resolution computed tomography in systemic sclerosis: real diagnostic utilities in the assessment of pulmonary involvement and comparison with other modalities of lung investigation. Clin Rheumatol 1992; 11:465-472
26. Muller NL, Colby TV. Idiopathic interstitial pneumonias: high-resolution CT and histologic findings. Radiographics 1997; 17:1016-1022
27. Latsi PI, Wells AU. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003; 15:748-755
28. Lynch DA. Nonspecific interstitial pneumonia: evolving concepts. Radiology 2001; 221:583-584
29. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165:277-304
30. Wells AU, Hansell DM, Corrin B, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992; 47:738-742
31. Ooi GC, Mok MY, Tsang KW, et al. Interstitial lung disease in systemic sclerosis. Acta Radiol 2003; 44:258-264
32. Saito Y, Terada M, Takada T, et al. Pulmonary involvement in mixed connective tissue disease: comparison with other collagen vascular diseases using high resolution CT. J Comput Assist Tomogr 2002; 26:349-357
33. Kim EA, Johkoh T, Lee KS, et al. Interstitial pneumonia in progressive systemic sclerosis: serial high-resolution CT findings with functional correlation. J Comput Assist Tomogr 2001; 25:757-763
34. Andonopoulos AP, Yarmenitis S, Georgiou P, et al. Bronchiectasis in systemic sclerosis: a study using high resolution computed tomography. Clin Exp Rheumatol 2001; 19:187-190
35. 1-antitrypsin measurement, and early detection of pulmonary involvement in patients with systemic sclerosis. Rheumatol Int 2001; 20:95-100
36. Akira M, Inoue G, Yamamoto S, et al. Non-specific interstitial pneumonia: findings on sequential CT scans of nine patients. Thorax 2000; 55:854-859
37. Hunninghake GW, Lynch DA, Galvin JR, et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003; 124:1215-1223
38. Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232:560-567
39. Colby TV, Carrington CB. Interstitial lung disease. In: Thurlbeck WM, Churg AM, eds. Pathology of the lung. New York, NY: Thieme Medical Publishers, 1995; 589-737
40. Piper WN, Helwig EB. Progressive systemic sclerosis; visceral manifestations in generalized scleroderma. AMA Arch Derm 1955; 72:535-546
41. Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177:91-98
42. Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37:1283-1289
43. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132:947-954
44. Clements PJ, Goldin JG, Kleerup EC, et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004; 50: 1909-1917